Alvotech (ALVO)
Nasdaq · Healthcare · Drug Manufacturers - Specialty & Generic
$6.11+12.11%as of Oct 6, 2026, 4:35 AM ET
- Market cap
- $2.2B
- Forward P/E
- 26.8
- 52-week range
- $2.94 – $9.05
- 52-week change
- −36.92%
- EPS (trailing)
- −$0.62
- Next earnings
- Nov 11, 2026
About Alvotech
Alvotech, through its subsidiaries, develops and manufactures biosimilar medicines for patients worldwide. It offers biosimilar products in the therapeutic areas of autoimmune, eye, and bone disorders, as well as cancer. The company provides AVT02, a high concentration, low-volume adalimumab formulation biosimilar to Humira to treat various inflammatory conditions, including rheumatoid arthritis, psoriatic arthritis, Crohn's disease, ankylosing spondylitis ulcerative colitis, and other indications; AVT04, a biosimilar to Stelara to treat various inflammatory conditions comprising psoriatic arthritis, Crohn's disease, ulcerative colitis, plaque psoriasis, and other indications; AVT06, a biosimilar to Eylea to treat various conditions, such as neovascular age-related macular degeneration, macular edema following retinal vein occlusion, diabetic macular edema and diabetic retinopathy; and AVT03, a biosimilar to Xgeva and Prolia to treat prevent bone fracture, spinal cord compression, and the need for radiation or bone surgery in patients with certain types of cancer, as well as prevent bone loss and increase bone mass.
Headquarters: Luxembourg, Luxembourg · 1,279 employees · alvotech.com